Bone marrow transplantation for chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Transplantation

Background:

• Chronic lymphocytic leukemia (CLL) treatment typically focuses on survival, not eradication.
• CLL predominantly affects older individuals, but younger patients (<50 years) present unique therapeutic challenges.
• Novel treatment strategies are needed for younger, refractory CLL cases.

Purpose of the Study:

• To evaluate the efficacy and outcomes of high-dose chemoradiotherapy and allogeneic bone marrow transplantation (BMT) in young patients with chronic lymphocytic leukemia (CLL).
• To assess the feasibility and safety of BMT as a potentially curative approach for refractory CLL in a younger demographic.

Main Methods:

• A review of existing literature and International Bone Marrow Transplant Registry (IBMTR) data was conducted.
• Analysis included 26 patients (24 allogeneic, 2 syngeneic) aged 21-49 years, predominantly with advanced, refractory CLL.
• Conditioning regimens involved cyclophosphamide and total body irradiation; graft-versus-host disease (GVHD) prophylaxis varied.

Main Results:

• Of 25 evaluable patients, 19 achieved remission, with 11 alive and disease-free at 5-48 months post-BMT.
• Early complications, including GVHD, infection, and hemorrhage, led to 12 deaths.
• Only two deaths were attributed to CLL progression; molecular studies indicated no residual disease in some survivors.

Conclusions:

• Allogeneic bone marrow transplantation (BMT) demonstrates promising results for achieving durable remission in selected young patients with chronic lymphocytic leukemia (CLL).
• Despite early complications, BMT offers a potential curative option, justifying further research and clinical trials.
• This approach warrants consideration for younger patients with advanced or refractory CLL who have not responded to conventional therapies.